MTOR and cholangiocarcinoma: In summary, an unbiased genome-wide CRISPR screen identified a synergistic combination effect between BETp and impairment of the mTOR pathway, leading to proofs of principle that combined small molecule BETi and mTORi can lead to efficacy against multiple CCA models.